Inflammation Drives Early Atherosclerosis Independently of Cholesterol and Blood Pressure
Inflammation drives atherosclerosis from its earliest stages, independently of cholesterol and blood pressure, according to a study led by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and published in the European Heart Journal.
- A CNIC imaging study published in the European Heart Journal found systemic inflammation contributes to early plaque development independently of LDL cholesterol and hypertension.
- Cardiologist Peter Libby told HCPLive that inflammation and traditional risk factors are not competitors but converging biological pathways — and that anti-inflammatory therapy remains a work in progress after the CANTOS trial.
- An artificial intelligence-derived measure of coronary inflammation, the fat attenuation index score, predicted cardiovascular events in the ORFAN study published in The Lancet in 2024 and may help select patients for anti-inflammatory treatment.
The CNIC findings come from an imaging study led by a team at the cardiovascular research center, with Guiomar Mendieta as first author and Dr. Valentín Fuster as co-lead.
The researchers observed that inflammation was associated not only with a greater burden of atherosclerotic plaque but also with more extensive disease across vascular territories, including the carotid, femoral, and coronary arteries. Fuster — CNIC general director, president of the Mount Sinai Fuster Heart Hospital, and physician-in-chief of the Mount Sinai Hospital in New York — presented the finding as a break from decades of earlier research.
Dr. Valentín Fuster, CNIC general director and co-lead author of the study, said the investigation takes a fresh methodological approach to demonstrate that inflammation is clearly involved in the very first phases of atherosclerosis formation, and that this contribution stands apart from the influence of other related variables, including cholesterol and blood pressure.
Atherosclerosis is a silent process that begins decades before a heart attack or stroke, with arteries accumulating fatty plaques and inflammatory cells without symptoms.
The research team concluded that integrating inflammatory biomarkers with advanced cardiovascular imaging could improve risk stratification and support prevention strategies aimed at stopping disease before clinical manifestations appear. The study was published in the European Heart Journal under the title “Inflammation and early atherosclerosis beyond traditional risk factors: an imaging study” (2026).
Libby rejects false dichotomy between risk factors and inflammation
Speaking with HCPLive, Libby, a cardiologist long associated with the inflammatory model of atherosclerosis, rejected any framing that pits conventional risk management against inflammation-targeted care. He called that framing a false dichotomy.
Peter Libby said that there is absolutely no competition between traditional risk factors and inflammation in an interview with HCPLive.
Libby described inflammation and immunity as the biological pathways through which hypertension, dyslipidemia, atherogenic lipoproteins, smoking, and oxidative stress converge. He characterized these pathways as protective mechanisms that turn against the host when activated in excess.
Where CANTOS left the field
CANTOS also showed a signal for infectious risk alongside fewer cancer deaths, particularly from lung cancer. Because of the oncology findings, the sponsor chose to develop canakinumab for cancer rather than cardiovascular disease.
Libby called CANTOS an important proof of concept for anti-inflammatory therapy while emphasizing that the work is far from finished. He anticipates a sequence of trials designed to pinpoint what he termed the “sweet spot,” in which anti-inflammatory effectiveness is maximized while adverse effects, such as weakened host defense and tumor surveillance, are kept to a minimum.
What established therapies may already be doing
Part of the answer may already sit in the standard of care. Libby told HCPLive that several established therapies may owe part of their benefit to anti-inflammatory activity, citing the pleiotropic effects of statins — and possibly bempedoic acid — as actions distinct from LDL cholesterol lowering. These dual effects may help explain the success of statins in reducing atherosclerotic events.
He drew a similar parallel with incretin mimetics. In this drug class, drops in high-sensitivity C-reactive protein (hs-CRP) appear ahead of meaningful weight reduction, just as metabolic gains precede significant weight loss following metabolic surgery. In other words, the inflammatory effect may be doing clinical work that the scale does not yet capture.
Imaging local inflammation beyond hs-CRP
hs-CRP performs well in cardiovascular prediction because it integrates inflammation from every source in the body, Libby told HCPLive — sources ranging from periodontal disease to infected diabetic foot ulcers, bronchitis, cystitis, inflammatory bowel disease, and autoinflammatory rheumatologic conditions.
Peter Libby told HCPLive that hs-CRP does not report on local inflammation and is agnostic as to the source.
To assess inflammation at the artery wall itself, Libby highlighted the fat attenuation index (FAI) score, derived from artificial intelligence analysis of routine coronary computed tomography angiography. The score reflects inflammation in the perivascular fat surrounding the coronary arteries.
In the ORFAN study, published in The Lancet in 2024 (Chan K, Wahome E, Tsiachristas A, et al.), the FAI score predicted cardiovascular events in a large population of patients undergoing clinically indicated CT scans.
It is still unresolved whether the FAI score can pinpoint patients at heightened local coronary risk who would qualify for anti-inflammatory treatment, and Libby characterized the idea of tracking score changes as an indicator of therapeutic response as, at this point, purely speculative. He stressed that the field urgently needs intermediate measures like this to support drug development.
Colchicine approved, more programs underway
One anti-inflammatory option has already entered routine practice: colchicine is now approved by the US Food and Drug Administration as an anti-inflammatory therapy for atherosclerotic disease. Numerous additional inflammation-focused programs are in progress, and Libby said that emerging imaging technologies might sharpen the selection of patients and tackle residual inflammatory risk in those whose conventional risk factors are already well managed.
The two lines of evidence — the CNIC imaging work showing inflammation operates at the disease’s earliest stages, and Libby’s argument that risk factors act through inflammatory pathways — point in the same direction.
They differ in emphasis: the CNIC team centers its conclusions on early-stage imaging and biomarker integration, while Libby’s account to HCPLive centers on therapeutics and trial design. Neither source reports a funded trial yet underway to test the FAI score as a treatment-response marker.
For patients with known coronary or carotid plaque, the practical question of whether local inflammation imaging should guide therapy is one for a treating cardiologist, ideally one practicing at a center with advanced cardiac CT capability; the sources do not yet support any change to current prevention guidelines.
What comes next, as Libby framed it to HCPLive, is finding the “sweet spot” between anti-inflammatory efficacy and the unwanted effects on host defense and tumor surveillance.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.